title: Oral bisphosphonates in polyostotic fibrous dysplasia.
abstract: The bisphosphonates inhibit osteoclastic bone resorption and have been used as an intravenous infusion in fibrous dysplasia of the bone. Oral bisphosphonates are cheaper and also easy to administer. We report a case of polyostotic fibrous dysplasia in a three-year-old child who showed significant improvement in bone mineral density after treatment with oral alendronate.
authors.affiliation: Growth and Pediatric Endocrine Unit, Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, 32 Sassoon Road, Pune 411 004, India. akhadilkar@vsnl.net
authors.forename: V V
authors.initials: VV
authors.lastname: Khadilkar
authors.forename: A V
authors.initials: AV
authors.lastname: Khadilkar
authors.forename: G B
authors.initials: GB
authors.lastname: Maskati
mesh_terms: D000284:Administration, Oral; D019386:Alendronate / Q000494:pharmacology / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D002675:Child, Preschool; D005359:Fibrous Dysplasia, Polyostotic / Q000188:drug therapy*; D006801:Humans; D008297:Male
chemical_list: D019386:Alendronate